RT Journal Article
SR Electronic
T1 Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20209114
DO 10.1101/2020.10.08.20209114
A1 Wu, Fan
A1 Yan, Renhong
A1 Liu, Mei
A1 Liu, Zezhong
A1 Wang, Yingdan
A1 Luan, Die
A1 Wu, Kaiyue
A1 Song, Zhigang
A1 Sun, Tingting
A1 Ma, Yunping
A1 Zhang, Yuanyuan
A1 Wang, Qimin
A1 Li, Xiang
A1 Ji, Ping
A1 Li, Yaning
A1 Li, Cheng
A1 Wu, Yanling
A1 Ying, Tianlei
A1 Wen, Yumei
A1 Jiang, Shibo
A1 Zhu, Tongyu
A1 Lu, Lu
A1 Zhang, Yongzhen
A1 Zhou, Qiang
A1 Huang, Jinghe
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.08.20209114.abstract
AB Antibody-dependent enhancement (ADE) has been reported in several virus infections including dengue fever virus, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus infection. To study whether ADE is involved in COVID-19 infections, in vitro pseudotyped SARS-CoV-2 entry into Raji cells, K562 cells, and primary B cells mediated by plasma from recovered COVID-19 patients were employed as models. The enhancement of SARS-CoV-2 entry into cells was more commonly detected in plasma from severely-affected elderly patients with high titers of SARS-CoV-2 spike protein-specific antibodies. Cellular entry was mediated via the engagement of FcγRII receptor through virus-cell membrane fusion, but not by endocytosis. Peptide array scanning analyses showed that antibodies which promote SARS-CoV-2 infection targeted the variable regions of the RBD domain. To further characterize the association between the spike-specific antibody and ADE, an RBD-specific monoclonal antibody (7F3) was isolated from a recovered patient, which potently inhibited SARS-Cov-2 infection of ACE-2 expressing cells and also mediated ADE in Raji cells. Site-directed mutagenesis the spike RBD domain reduced the neutralization activity of 7F3, but did not abolish its binding to the RBD domain. Structural analysis using cryo-electron microscopy (Cryo-EM) revealed that 7F3 binds to spike proteins at a shift-angled pattern with one “up” and two “down” RBDs, resulting in partial overlapping with the receptor binding motif (RBM), while a neutralizing monoclonal antibody that lacked ADE activity binds to spike proteins with three “up” RBDs, resulting in complete overlapping with RBM. Our results revealed that ADE mediated by SARS-CoV-2 spike-specific antibodies could result from binding to the receptor in slightly different pattern from antibodies mediating neutralizations. Studies on ADE using antibodies from recovered patients via cell biology and structural biology technology could be of use for developing novel therapeutic and preventive measures for control of COVID-19 infection.Competing Interest StatementPatents about the monoclonal antibodies 7F3 and 4L12 in this study are pending.Funding StatementThis work was supported by the National Natural Science Foundation of China (31771008 to JH, 31930001 to YZ and FW, 82041025 to SJ, and 31971123 to QZ), the National Major Science and Technology Projects of China (2017ZX10202102 to JH and 2018ZX10301403 to FW and LL), Hundred Talent Program of Shanghai Municipal Health Commission (2018BR08 to JH), Chinese Academy of Medical Sciences (2019PT350002 to JH), Program of Shanghai Academic/Technology Research Leader (20XD1420300 to LL), the Key R&D Program of Zhejiang Province (2020C04001), the SARS-CoV-2 Emergency Project of the Science and Technology Department of Zhejiang Province (2020C03129), the Leading Innovative and Entrepreneur Team Introduction Program of Hangzhou, and the Special Research Program of Novel Coronavirus Pneumonia of Westlake University and Tencent foundation to QZ.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted under a clinical protocol approved by the Investigational Review Board in the Shanghai Public Health Clinical Center (Study number: YJ-2020-S018-02).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCorrespondence and requests for all data should be addressed to Jinghe Huang (jinghehuang@fudan.edu.cn)